These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25085754)

  • 1. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
    Wang F; Yang Y
    Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
    Zhang X; Bai W
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):655-9. PubMed ID: 27473325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
    Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
    Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
    Habib E; Linher-Melville K; Lin HX; Singh G
    Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.
    Wu YM; Chen ZJ; Jiang GM; Zhang KS; Liu Q; Liang SW; Zhou Y; Huang HB; Du J; Wang HS
    Oncotarget; 2016 Mar; 7(11):12568-81. PubMed ID: 26871469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
    Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
    Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
    Yoshikawa M; Tsuchihashi K; Ishimoto T; Yae T; Motohara T; Sugihara E; Onishi N; Masuko T; Yoshizawa K; Kawashiri S; Mukai M; Asoda S; Kawana H; Nakagawa T; Saya H; Nagano O
    Cancer Res; 2013 Mar; 73(6):1855-66. PubMed ID: 23319806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
    Linher-Melville K; Nashed MG; Ungard RG; Haftchenary S; Rosa DA; Gunning PT; Singh G
    PLoS One; 2016; 11(8):e0161202. PubMed ID: 27513743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Redox regulation in cancer stem cells].
    Saya H
    Nihon Rinsho; 2015 May; 73(5):790-4. PubMed ID: 25985632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Ju HQ; Lu YX; Chen DL; Tian T; Mo HY; Wei XL; Liao JW; Wang F; Zeng ZL; Pelicano H; Aguilar M; Jia WH; Xu RH
    Theranostics; 2016; 6(8):1160-75. PubMed ID: 27279909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
    Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation.
    Long Y; Xu Z; Yu J; Hu X; Xie Y; Duan X; Li N; Yan Y; Wang Y; Qin J
    Anticancer Drugs; 2024 Oct; 35(9):830-843. PubMed ID: 39016262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-escalation study for the targeting of CD44v
    Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
    Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.
    Thanee M; Loilome W; Techasen A; Sugihara E; Okazaki S; Abe S; Ueda S; Masuko T; Namwat N; Khuntikeo N; Titapun A; Pairojkul C; Saya H; Yongvanit P
    Cancer Sci; 2016 Jul; 107(7):991-1000. PubMed ID: 27176078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of anethole and doxorubicin alleviates cell proliferation, cell cycle arrest, and ER stress and promotes ROS-mediated apoptosis in triple-negative breast cancer cells.
    Arumugam P; Sampathkumar B; Perumalsamy H; Balusamy SR; Ramesh V; Sundaravadevel S
    J Biochem Mol Toxicol; 2021 Dec; 35(12):e22928. PubMed ID: 34585488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
    Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
    Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.
    Wada T; Ishimoto T; Seishima R; Tsuchihashi K; Yoshikawa M; Oshima H; Oshima M; Masuko T; Wright NA; Furuhashi S; Hirashima K; Baba H; Kitagawa Y; Saya H; Nagano O
    Cancer Sci; 2013 Oct; 104(10):1323-9. PubMed ID: 23848514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
    Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
    Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipocalin 2 attenuates iron-related oxidative stress and prolongs the survival of ovarian clear cell carcinoma cells by up-regulating the CD44 variant.
    Yamada Y; Miyamoto T; Kashima H; Kobara H; Asaka R; Ando H; Higuchi S; Ida K; Shiozawa T
    Free Radic Res; 2016; 50(4):414-25. PubMed ID: 26729415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.